Stratrix
Company data sheet · Merck

Merck: profitable every year.

Industry
Pharmaceutical Preparations Manufacturing
Headquarters
United States
Ticker
MRK (NYSE)
Sources
SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
Data as of
October 18, 2026
  1. Two decisions on record. Stratrix has verified two of Merck's big decisions, each with what happened next. The hardest year after: "Merck's Vioxx Recall Is Taught as a Model of Responsibility. The Paper Trail Says Otherwise", with its shares 23 points behind the S&P 500 over the next three years.
  2. Profitable every year. Merck made money in each of its last ten fiscal years, from $0.4 billion (2023) to $18.3 billion (2025).

Financial results

Fiscal yearRevenueNet income
2016$39.8 billion$3.9 billion
2017$40.1 billion$2.4 billion
2018$42.3 billion$6.2 billion
2019$39.1 billion$9.8 billion
2020$41.5 billion$7.1 billion
2021$48.7 billion$13 billion
2022$59.3 billion$14.5 billion
2023$60.1 billion$0.4 billion
2024$64.2 billion$17.1 billion
2025$65 billion$18.3 billion

As reported in its annual filings. Losses in red.

Stratrix Decision Cases

The full data sheet · Data Plan

Everything behind these findings, ready for your board deck.

  • Market reaction to disclosed decisions: 21 decision filings since 2016, each linked to the SEC, with the share return against its sector and the S&P 500 the next day and the next year (21 with market data).
  • Economic context: 7 measures for the United States, every year since 2016, from the official sources.
  • Peer comparison: against 264 companies of its size in its sector.
  • Financial results: ten years of revenue, operating and net income, and every annual report, linked.
  • Methods and sources, so each number can be checked and cited.
Download the PDFDownload the ExcelSee the Data Plan

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.